CD1a dendritic cells predominate in transitional cell carcinoma of bladder and kidney but are minimally activated

Journal of Urology

Volumn 161, Issue 6, 1999, Pages 1962-1967

  Troy, Andrew J ^b   Davidson, Peter J T ^b   Atkinson, Christopher H ^b   Hart, Derek N J ^a,b  

^a MATER MEDICAL RESEARCH INSTITUTE   (Australia)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

Bladder tumour immunology; Dendritic cells; Langerhans cells

Indexed keywords

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; BLADDER CARCINOMA; CELL ACTIVATION; CELL COUNT; DENDRITIC CELL; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; TRANSITIONAL CELL CARCINOMA; TUMOR CELL;

EID: 0032875801     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)68864-7     Document Type: Article

References (33)

1. Hart, D. N. J.: Dendritic cells: unique leucocyte populations which control the primary immune response. Blood, 90: 3245, 1997.
2. Boon, T., Cerottini, J. C., Eynde, B., Bruggen, P. and Pel, A. V.: Tumor antigens recognized by T lymphocytes. Ann. Rev. Immunol., 12: 337, 1994.
3. Davis, A. L., McKenzie, J. L. and Hart, D. N. J.: HLA-DR positive leukocyte subpopulations in human skin include dendritic cells, macrophages and CD7-negative T cells. Immunology, 65: 573, 1988.
4. Nestle, F. O., Zheng, X., Thompson, C. B., Turka, L. A. and Nickoloff, B. J.: Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. J. Immunol., 151: 6535, 1993.
5. Lanzavecchia, A.: Mechanisms of antigen uptake for presentation. Curr. Opin. Immunol., 8: 348, 1996.
6. Watts, C.: Capture and processing of exogenous antigens for presentation on MHC molecules. Ann. Rev. Immunol., 15: 821, 1997.
7. Guinan, E. C., Gribben, J. G., Boussiotis, V. A., Freeman, G. J. and Nadler, L. M.: Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood, 84: 3261, 1994.
8. Inoue, K., Furihata, M., Ohtsuki, Y. and Fujita, Y.: Distribution of S-100 protein-positive dendritic cells and expression of HLA-DR antigen in transitional cell carcinoma of the urinary bladder in relation to tumour progression and prognosis. Pathol. Anat. Histopathol., 422: 351, 1993.
9. Ioachim-Velogianni, E., Stavropoulos, N. E., Kitsiou, E., Stefanaki, S. and Agnantis, N. J.: Distribution of CD1A-positive langerhans cells and lymphocyte subsets in transitional cell carcinoma of the urinary bladder. An immunohistological study on frozen sections. J. Pathol., 177: 401, 1995.
10. Kahn, H. J., Marks, A., Thom, H. and Baumal, R.: Role of antibody to S100 protein in diagnostic pathology. Am. J. Clin. Pathol., 79: 341, 1983.
11. Troy, A. J., Summers, K. L., Davidson, P. J. T., Atkinson, C. A. and Hart, D. N. J.: The dendritic cell infiltrate in human renal cell carcinoma: a probable mechanism for tumor escape from immune surveillance. Clin. Cancer Res., 4: 585, 1998.
12. Egner, W., Andreesen, R. and Hart, D. N. J.: Allostimulatory cells in fresh human blood: heterogeneity in antigen presenting cell populations. Transplantation, 56: 945, 1993.
13. Zhou, L. J. and Tedder, T. F.: Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J. Immunol., 154: 3821, 1995.
14. Hock, B. D., Starling, G. C., Daniel, P. B. and Hart, D. N. J.: Characterisation of CMRF-44, a novel monoclonal antibody to an activation antigen expressed by the allostimulatory cells within peripheral blood, including dendritic cells. Immunology, 83: 573, 1994.
15. Troy, A. and Hart, D. N. J.: Dendritic cells in cancer: progress towards a new cellular therapy. J. Hematother., 6: 523, 1997.
16. Young, J. W. and Inaba, K.: Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J. Exp. Med., 183: 7, 1996.
17. Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engelman, E. G. and Levy, R.: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med., 2: 52, 1996.
18. Murphy, G., Tjoa, B., Ragde, H., Kenny, G. and Boynton, A.: Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate, 29: 371, 1996.
19. Troy, A., Davidson, P., Atkinson, C. and Hart, D.: Phenotypic characterization of the dendritic cell infiltrate in prostate cancer. J. Urol., 160: 214, 1998.
20. + phenotype. J. Invest. Dermatol., 111: 841, 1998.
21. Fearnley, D. B., McLellan, A. D., Mannering, S. I., Hock, B. D. and Hart, D. N. J.: Isolation of human blood dendritic cells using the CMRF-44 monoclonal antibody: implications for studies on antigen presenting cell function and immunotherapy. Blood, 89: 3708, 1997.
22. Gabrilovich, D. I., Corak, J., Ciernik, I. F., Kavanaugh, D. and Carbone, D. P.: Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res., 3: 483, 1997.
23. Chaux, P., Favre, N., Martin, M. and Martin, F.: Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int. J. Cancer, 72: 619, 1997.
24. Golumbek, P., Levitsky, H., Jaffee, L. and Pardoll, D. M.: The antitumor immune response as a problem of self-nonself discrimination: Implications for immunotherapy. Immunol. Rev., 12: 183, 1993.
25. Roake, J. A., Rao, A. S., Morris, P. J., Larsen, C. P., Hankins, D. F. and Austyn, J. M.: Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide tumor necrosis factor and interleukin 1. J. Exp. Med., 181: 2237, 1995.
26. Sozzani, S., Luini, W., Borsatti, A., Polentarutti, N., Zhou, D., Piemonti, L., D'Amico, G., Power, C. A., Wells, T. N. C., Gobbi, M., Allavena, P. and Mantovani, A.: Receptor expression and responsiveness of human dendritic cells to a defined set of CC and CXC chemokines. J. Immunol., 159: 1993, 1997.
27. Knoefel, B., Nuske, K., Steiner, T., Junker, K., Kosmehl, H., Rebstock, K., Heinhold, D. and Junker, U.: Renal cell carcinomas produce IL-6, 1-10, IL-11, and TGF-beta 1 in primary cultures and modulate T lymphocyte blast information. J. Interferon Cytokine Res., 17: 95, 1997.
28. Maffezzini, M., Simonato, A. and Fortis, C.: Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL-2) and alpha-interferon (A-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatment. Prostate, 28: 282, 1996.
29. Willems, F., Marchant, A., Delville, J., Gerard, C., Delvaux, A., Velu, T., de Boer, M. and Goldman, M.: Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur. J. Immunol., 24: 1007, 1994.
30. Eder, I. E., Stenzl, A., Hobisch, A., Cronauer, M. V., Bartsch, G. and Klocker, H.: Expression of transforming growth factors beta-1, beta-2 and beta-3 in human bladder carcinomas. Br. J. Cancer, 75: 1753, 1997.
31. O'Brien, T., Cranston, D., Fuggle, S., Bicknell, R. and Harris, A. L.: Different angiogenic pathways characterized superficial and invasive bladder cancer. Cancer Res., 55: 510, 1997.
32. Prescott, S., James, K., Hargreave, T. B., Chisholm, G. D. and Smyth, J. F.: Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J. Urol., 147: 1636, 1992.
33. Thurnher, M., Ramoner, R., Gastl, G., Radmayr, C., Bock, G., Harold, M., Klocker, H. and Bartsch, G.: Bacillus Calmette-Guerin mycobacteria stimulate human blood dendritic cells. Int. J. Cancer, 70: 128, 1997.